277 related articles for article (PubMed ID: 33092124)
1. Are Viral Vectors Any Good for RNAi Antiviral Therapy?
Lundstrom K
Viruses; 2020 Oct; 12(10):. PubMed ID: 33092124
[TBL] [Abstract][Full Text] [Related]
2. Viral Vectors Applied for RNAi-Based Antiviral Therapy.
Lundstrom K
Viruses; 2020 Aug; 12(9):. PubMed ID: 32842491
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors.
Becker J; Stanifer ML; Leist SR; Stolp B; Maiakovska O; West A; Wiedtke E; Börner K; Ghanem A; Ambiel I; Tse LV; Fackler OT; Baric RS; Boulant S; Grimm D
Mol Ther; 2022 May; 30(5):2005-2023. PubMed ID: 35038579
[TBL] [Abstract][Full Text] [Related]
4. Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.
Sun Y; Li Z; Li L; Li J; Liu X; Li W
Int J Mol Med; 2007 Apr; 19(4):705-11. PubMed ID: 17334648
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: Rescue by transcriptional inhibition.
Shilatifard A
Sci Adv; 2020 Jul; 6(27):. PubMed ID: 32937442
[No Abstract] [Full Text] [Related]
6. Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.
Herrera-Carrillo E; Liu YP; Berkhout B
Hum Gene Ther Methods; 2017 Aug; 28(4):177-190. PubMed ID: 28712309
[TBL] [Abstract][Full Text] [Related]
7. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
[TBL] [Abstract][Full Text] [Related]
8. Efficient silencing of hepatitis B virus by helper-dependent adenovirus vector-mediated delivery of artificial antiviral primary micro RNAs.
Mowa MB; Crowther C; Ely A; Arbuthnot P
Microrna; 2012; 1(1):19-25. PubMed ID: 25048086
[TBL] [Abstract][Full Text] [Related]
9. Potential use of noncoding RNAs and innovative therapeutic strategies to target the 5'UTR of SARS-CoV-2.
Baldassarre A; Paolini A; Bruno SP; Felli C; Tozzi AE; Masotti A
Epigenomics; 2020 Aug; 12(15):1349-1361. PubMed ID: 32875809
[TBL] [Abstract][Full Text] [Related]
10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
11. Discovering small-molecule therapeutics against SARS-CoV-2.
Tiwari V; Beer JC; Sankaranarayanan NV; Swanson-Mungerson M; Desai UR
Drug Discov Today; 2020 Aug; 25(8):1535-1544. PubMed ID: 32574699
[TBL] [Abstract][Full Text] [Related]
12. Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo.
Li B; Sun S; Li M; Cheng X; Li H; Kang F; Kang J; Dörnbrack K; Nassal M; Sun D
Antiviral Res; 2016 Oct; 134():117-129. PubMed ID: 27591142
[TBL] [Abstract][Full Text] [Related]
13. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
14. A protein interaction map identifies existing drugs targeting SARS-CoV-2.
Cava C; Bertoli G; Castiglioni I
BMC Pharmacol Toxicol; 2020 Sep; 21(1):65. PubMed ID: 32883368
[TBL] [Abstract][Full Text] [Related]
15. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
16. DNA vector-based RNA interference to study gene function in cancer.
Stovall DB; Wan M; Zhang Q; Dubey P; Sui G
J Vis Exp; 2012 Jun; (64):e4129. PubMed ID: 22710444
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microRNA cluster.
Yang X; Haurigot V; Zhou S; Luo G; Couto LB
Hepatology; 2010 Dec; 52(6):1877-87. PubMed ID: 20931557
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Delivery of Cassettes Encoding Anti-HBV Primary MicroRNAs Using an Ancestral Adeno-Associated Viral Vector.
Mnyandu N; Arbuthnot P; Maepa MB
Methods Mol Biol; 2020; 2115():171-183. PubMed ID: 32006401
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract.
Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550
[TBL] [Abstract][Full Text] [Related]
20. Efficient Gene Suppression in Dorsal Root Ganglia and Spinal Cord Using Adeno-Associated Virus Vectors Encoding Short-Hairpin RNA.
Enomoto M; Hirai T; Kaburagi H; Yokota T
Methods Mol Biol; 2016; 1364():277-90. PubMed ID: 26472458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
